Skip to main content
. 2019 Dec 14;2019:8245810. doi: 10.1155/2019/8245810

Figure 2.

Figure 2

MALAT1 and miR-181b expression in AS patients and oxLDL-treated HUVECs. (a, b) Levels of circulating lncRNA MALAT1 and miR-181b in healthy volunteers and AS patients measured by RT-PCR. P < 0.05 versus the control group. (c–h) Relative expression of MALAT1, miR-181b, and TOX about 24 h after treating with various concentrations of oxLDL (0, 50, 100, 150, and 200 μg/ml) or treating with oxLDL (150 μg/ml) for different times. P < 0.05 versus the control group.